Drug Target Clinical phase indications comments Reference
HOE-140 (Icatibant) B2R antagonist Approved Hereditary angioedema Shortened the duration of acute attacks [41]
Phases I-IV Cardiopulmonary bypass, inflammation, fibrinolysis, surgery, ischaemic heart diseases, ischaemic reperfusion, heart failure, ACE inhibitor associated angioedema, angioneurotic edema Many completed and ongoing studies. Decreased intraoperative fibrinolytic capacity in cardiopulmonary bypass. No efficacy demonstrated for angioedema and ischemia-reperfusion injury [45-47]
Phase II Mitochondria and chronic kidney disease Completed, no evidence of efficacy NCT03177798
Phase II Knee pain in osteoarthritis Completed, results not available NCT00303056
MEN16132 (Fasitibant) B2R antagonist Phase II Knee pain in osteoarthritis Two studies completed. No direct evidence of efficacy, treated patients used less rescue medication. NCT01091116 NCT02205814